Form DEFA14A AMARIN CORP PLC\UK streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Investegate announcements from Amarin Corporation plc, New REDUCE-IT® Data Show VASCEPA®/VAZKEPA® (icosapent ethyl) Reduced STEMI as Well as Other MI Subtypes
Late-Breaking Data Show VASCEPA/VAZKEPA Significantly Reduced STEMI by 40% and NSTEMI by 27% in Pre-Specified, Post Hoc Analyses Data Presented During Late-Breaking Science Session at European
Amarin Receives Positive CHMP Opinion for Icosapent Ethyl for Cardiovascular Risk Reduction
Positive opinion is based on extensive clinical study results, including results of the REDUCE-IT
® cardiovascular outcomes study
European Commission decision on the Marketing Authorisation Application expected in April 2021
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 29, 2021 (GLOBE NEWSWIRE) Amarin Corporation plc (NASDAQ:AMRN) today announced that in response to Amarin’s Marketing Authorisation Application submission, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending that a marketing authorisation be granted to icosapent ethyl in the European Union for the reduction of risk of cardiovascular events in patients at high cardiovascular risk, under the brand name VAZKEPA